Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000303
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 2
---
 6-K filing for the month of December
2024, and incorporated by reference herein, is:

| 2 |

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: December 4, 2024 | Biodexa Pharmaceuticals PLC 
 By:                         | /s/ Stephen Stamp                                   |
|:-----------------------|:----------------------------|:----------------------------------------------------|
|                        |                             | Stephen Stamp                                       |
|                        |                             | Chief Executive Officer and Chief Financial Officer |

| 3 |

Exhibit 99.1

November 22, 2024

<div align='center'>Biodexa Pharmaceuticals PLC

(“Biodexa” or the “Company”)

Result of General Meeting</div>

Biodexa Pharmaceuticals PLC (“Biodexa”
or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products
for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, both resolutions
put to the Company’s shareholders were duly passed.

The full text of, inter alia, the resolutions
proposed and passed at the Annual General Meeting and General Meeting can be found in the Notice of the General Meeting on the Company's
website at: https://biodexapharma.com/investors/corporate-governance/#agms.

The effect of the resolutions is solely
to reduce the nominal, or par, value per ordinary share. There is no change to the number of ordinary shares outstanding.

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ:
BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet
medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle
Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive
rare/orphan brain cancer indications.

eRapa is a proprietary oral tablet formulation
of rapamycin, also known as sirolimus. Rapamycin is an mTOR (m